Open AccessInfusion‐related reactions to Rituximab: pathogenic mechanism and proposal of a new modified desensitization protocol
Author(s) -
Ramirez Luis F,
Cañas Carlos,
Tobon Gabriel,
Bonilla Fabio,
Olaya Manuela,
Serrano Carlos
Publication year - 2014
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-4-s3-p55
Subject(s) - medicine , desensitization (medicine) , rituximab , premedication , drug allergy , omalizumab , allergy , loratadine , immunology , immunoglobulin e , pharmacology , anesthesia , antibody , receptor
Background Rituximab is a chimeric monoclonal antibody against the surface protein CD20 of B cells, used in the treatment of hematologic malignances and autoimmune diseases. Some patients develop hypersensitivity reactions after the infusion. It is unknown the percentage of these which are due to an IgE allergic mechanism. Also, there is not a standardized desensitization protocol that allows us to induce tolerance to this drug in patients.